Cargando…
The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada
This article identifies the potential sources of inequity in three stages of integrating cystic fibrosis personalized medicines into the Canadian healthcare system and proposes mitigating strategies: (1) clinical research and diagnostic testing; (2) regulatory oversight and market authorization; and...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151662/ https://www.ncbi.nlm.nih.gov/pubmed/34067090 http://dx.doi.org/10.3390/jpm11050382 |
_version_ | 1783698436088922112 |
---|---|
author | Shemie, Genevieve Nguyen, Minh Thu Wallenburg, John Ratjen, Felix Knoppers, Bartha Maria |
author_facet | Shemie, Genevieve Nguyen, Minh Thu Wallenburg, John Ratjen, Felix Knoppers, Bartha Maria |
author_sort | Shemie, Genevieve |
collection | PubMed |
description | This article identifies the potential sources of inequity in three stages of integrating cystic fibrosis personalized medicines into the Canadian healthcare system and proposes mitigating strategies: (1) clinical research and diagnostic testing; (2) regulatory oversight and market authorization; and (3) implementation into the healthcare system. There is concern that differential access will cast a dark shadow over personalized medicine by stratifying the care that groups of patients will receive—not only based on their genetic profiles, but also on the basis of their socioeconomic status. Furthermore, there is a need to re-evaluate regulatory and market approval mechanisms to accommodate the unique nature of personalized medicines. Physical and financial accessibility ought to be remedied before personalized medicines can be equitably delivered to patients. This article identifies the socio–ethical and legal challenges at each stage and recommends mitigating policy solutions. |
format | Online Article Text |
id | pubmed-8151662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81516622021-05-27 The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada Shemie, Genevieve Nguyen, Minh Thu Wallenburg, John Ratjen, Felix Knoppers, Bartha Maria J Pers Med Review This article identifies the potential sources of inequity in three stages of integrating cystic fibrosis personalized medicines into the Canadian healthcare system and proposes mitigating strategies: (1) clinical research and diagnostic testing; (2) regulatory oversight and market authorization; and (3) implementation into the healthcare system. There is concern that differential access will cast a dark shadow over personalized medicine by stratifying the care that groups of patients will receive—not only based on their genetic profiles, but also on the basis of their socioeconomic status. Furthermore, there is a need to re-evaluate regulatory and market approval mechanisms to accommodate the unique nature of personalized medicines. Physical and financial accessibility ought to be remedied before personalized medicines can be equitably delivered to patients. This article identifies the socio–ethical and legal challenges at each stage and recommends mitigating policy solutions. MDPI 2021-05-07 /pmc/articles/PMC8151662/ /pubmed/34067090 http://dx.doi.org/10.3390/jpm11050382 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Shemie, Genevieve Nguyen, Minh Thu Wallenburg, John Ratjen, Felix Knoppers, Bartha Maria The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada |
title | The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada |
title_full | The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada |
title_fullStr | The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada |
title_full_unstemmed | The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada |
title_short | The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada |
title_sort | equitable implementation of cystic fibrosis personalized medicines in canada |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151662/ https://www.ncbi.nlm.nih.gov/pubmed/34067090 http://dx.doi.org/10.3390/jpm11050382 |
work_keys_str_mv | AT shemiegenevieve theequitableimplementationofcysticfibrosispersonalizedmedicinesincanada AT nguyenminhthu theequitableimplementationofcysticfibrosispersonalizedmedicinesincanada AT wallenburgjohn theequitableimplementationofcysticfibrosispersonalizedmedicinesincanada AT ratjenfelix theequitableimplementationofcysticfibrosispersonalizedmedicinesincanada AT knoppersbarthamaria theequitableimplementationofcysticfibrosispersonalizedmedicinesincanada AT shemiegenevieve equitableimplementationofcysticfibrosispersonalizedmedicinesincanada AT nguyenminhthu equitableimplementationofcysticfibrosispersonalizedmedicinesincanada AT wallenburgjohn equitableimplementationofcysticfibrosispersonalizedmedicinesincanada AT ratjenfelix equitableimplementationofcysticfibrosispersonalizedmedicinesincanada AT knoppersbarthamaria equitableimplementationofcysticfibrosispersonalizedmedicinesincanada |